ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers (Q39290058)

10 September 2017

title

ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers (English)

1 reference

10 September 2017

2

1 reference

10 September 2017

A P Rebocho

1

1 reference

10 September 2017

language of work or name

English

0 references

publication date

27 August 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

32

1 reference

10 September 2017

issue

26

1 reference

10 September 2017

page(s)

3207-3212

1 reference

Mutations of the BRAF gene in human cancer

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

The RAF proteins take centre stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

New insight into BRAF mutations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Mutational analysis of the ARAF gene in human cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Positive and negative regulation of Raf kinase activity and function by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Guilty as charged: B-RAF is a human oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2012.330

21 January 2018

Identifiers

DOI

10.1038/ONC.2012.330

1 reference

10 September 2017

1 reference